Compare RGCO & RNAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RGCO | RNAC |
|---|---|---|
| Founded | 1912 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 232.9M | 204.6M |
| IPO Year | N/A | 2016 |
| Metric | RGCO | RNAC |
|---|---|---|
| Price | $22.23 | $7.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $38.40 |
| AVG Volume (30 Days) | 9.6K | ★ 110.5K |
| Earning Date | 11-19-2025 | 11-06-2025 |
| Dividend Yield | ★ 3.77% | N/A |
| EPS Growth | ★ 11.26 | N/A |
| EPS | ★ 1.29 | N/A |
| Revenue | ★ $95,334,212.00 | $1,091,000.00 |
| Revenue This Year | $9.00 | N/A |
| Revenue Next Year | $8.30 | N/A |
| P/E Ratio | $17.10 | ★ N/A |
| Revenue Growth | ★ 12.63 | N/A |
| 52 Week Low | $19.06 | $5.98 |
| 52 Week High | $23.82 | $26.50 |
| Indicator | RGCO | RNAC |
|---|---|---|
| Relative Strength Index (RSI) | 58.49 | 38.43 |
| Support Level | $21.98 | $7.23 |
| Resistance Level | $22.83 | $7.73 |
| Average True Range (ATR) | 0.64 | 0.42 |
| MACD | 0.13 | 0.07 |
| Stochastic Oscillator | 75.90 | 12.73 |
RGC Resources Inc is involved in the business of distribution and sale of natural gas to residential, commercial, and industrial customers within its service territory in Roanoke, Virginia, and its surrounding localities. The company also provides certain non-regulated services. The company relies on multiple interstate pipelines to transport natural gas. The company operates in three segments: Gas Utility, which is the key revenue generator; Investment in Affiliates this segment reflects the income generated through the activities of the Company's investment in MVP and Southgate projects and Parent & Other including the unregulated activities of the Company as well as certain corporate eliminations.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.